Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
51 hedge funds and large institutions have $115M invested in Sierra Oncology, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 9 closing their positions.
156% more capital invested
Capital invested by funds: $45M → $115M (+$70.4M)
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
24% more funds holding
Funds holding: 41 → 51 (+10)
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$3.23M |
| 2 |
6CM
683 Capital Management
New York
|
+$2.21M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$1.44M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.32M |
| 5 |
Renaissance Technologies
New York
|
+$996K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3M |
| 2 |
DM
Deerfield Management
New York
|
-$2.5M |
| 3 |
O
OrbiMed
New York
|
-$1.2M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$827K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$308K |
SRRA Hedge Fund Activity: Q4 2017 in Review
51 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q4 2017, worth a combined $115M — up 156% from $45M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new SRRA positions and 9 closed out — a net gain of 10 holders — while 9 added to existing stakes and 8 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $3.23M. The largest seller was Point72 Asset Management, cutting an estimated $3M.
- 51 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q4 2017, up from 41 in Q3 2017.
- Funds reported $115M of Sierra Oncology, Inc. Common Stock stock for Q4 2017, up 156% quarter-over-quarter.
- 19 funds opened new Sierra Oncology, Inc. Common Stock positions in Q4 2017 and 9 closed out, a net change of +10 holders.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q4 2017 was Perceptive Advisors, an estimated $3.23M added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q4 2017 was Point72 Asset Management, an estimated $3M sold.
Based on aggregated 13F filings for Q4 2017.